Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.

Q2 Medicine HIV Clinical Trials Pub Date : 2018-02-01 Epub Date: 2017-11-28 DOI:10.1080/15284336.2017.1404690
E Molas, S Luque, A Retamero, D Echeverría-Esnal, A Guelar, M Montero, R Guerri, L Sorli, E Lerma, J Villar, H Knobel
{"title":"Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.","authors":"E Molas,&nbsp;S Luque,&nbsp;A Retamero,&nbsp;D Echeverría-Esnal,&nbsp;A Guelar,&nbsp;M Montero,&nbsp;R Guerri,&nbsp;L Sorli,&nbsp;E Lerma,&nbsp;J Villar,&nbsp;H Knobel","doi":"10.1080/15284336.2017.1404690","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Interactions between antiretroviral treatment (ART) and comedications are a concern in HIV-infected patients. This study aimed to determine the frequency and severity of potential drug-drug interactions (PDDIs) with ART in our setting.</p><p><strong>Methods: </strong>Observational study by a multidisciplinary team in 1259 consecutive HIV patients (March 2015-September 2016). Data on demographics, toxic habits, comorbidities, and current ART were collected. A structured questionnaire recorded concomitant medications (including occasional and over-the-counter drugs). PDDIs were classified into four categories: (1) no interactions, (2) mild (clinically non-significant), (3) moderate (requiring close monitoring or drug modification/dose adjustment), and (4) severe (contraindicated).</p><p><strong>Statistical analysis: </strong>chi-square test, logistic regression analysis.</p><p><strong>Results: </strong>In total, 881 (70%) patients took comedication, and 563 (44.7%) had ≥ PDDI. Forty-one comedicated patients (4.6%) had severe and 522 (59.2%) moderate PDDIs. Moderate PDDIs mainly involved cardiovascular (53.8%) and central nervous system (40.2%) drugs. Independent risk factors for PDDIs were ART containing a boosted protease inhibitor (odds ratio [OR]=9.11, 95% confidence interval [CI] 5.15-16.11; p = 0.0001) and/or non-nucleoside reverse transcriptase (NNRTI) (OR = 4.34, 95%CI 2.49-7.55; p = 0.0001), HCV co-infection (OR = 3.26, 95%CI 2.15-4.93; p = 0.0001), and use of two or more comedications (OR = 3.36, 95%CI 2.27-4.97; p = 0.0001). Adherence and effectiveness of ART were similar in patients with and without PDDIs. The team made 133 recommendations related to comedications (drug change or dose adjustment) or ART (drug switch or change in administration schedule).</p><p><strong>Conclusions: </strong>Systematic evaluation detected a significant percentage of PDDIs requiring an intervention in HIV patients on ART. Monitoring and advice about drug-drug interactions should be part of routine practice.</p>","PeriodicalId":13216,"journal":{"name":"HIV Clinical Trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/15284336.2017.1404690","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15284336.2017.1404690","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/11/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 22

Abstract

Objectives: Interactions between antiretroviral treatment (ART) and comedications are a concern in HIV-infected patients. This study aimed to determine the frequency and severity of potential drug-drug interactions (PDDIs) with ART in our setting.

Methods: Observational study by a multidisciplinary team in 1259 consecutive HIV patients (March 2015-September 2016). Data on demographics, toxic habits, comorbidities, and current ART were collected. A structured questionnaire recorded concomitant medications (including occasional and over-the-counter drugs). PDDIs were classified into four categories: (1) no interactions, (2) mild (clinically non-significant), (3) moderate (requiring close monitoring or drug modification/dose adjustment), and (4) severe (contraindicated).

Statistical analysis: chi-square test, logistic regression analysis.

Results: In total, 881 (70%) patients took comedication, and 563 (44.7%) had ≥ PDDI. Forty-one comedicated patients (4.6%) had severe and 522 (59.2%) moderate PDDIs. Moderate PDDIs mainly involved cardiovascular (53.8%) and central nervous system (40.2%) drugs. Independent risk factors for PDDIs were ART containing a boosted protease inhibitor (odds ratio [OR]=9.11, 95% confidence interval [CI] 5.15-16.11; p = 0.0001) and/or non-nucleoside reverse transcriptase (NNRTI) (OR = 4.34, 95%CI 2.49-7.55; p = 0.0001), HCV co-infection (OR = 3.26, 95%CI 2.15-4.93; p = 0.0001), and use of two or more comedications (OR = 3.36, 95%CI 2.27-4.97; p = 0.0001). Adherence and effectiveness of ART were similar in patients with and without PDDIs. The team made 133 recommendations related to comedications (drug change or dose adjustment) or ART (drug switch or change in administration schedule).

Conclusions: Systematic evaluation detected a significant percentage of PDDIs requiring an intervention in HIV patients on ART. Monitoring and advice about drug-drug interactions should be part of routine practice.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过多学科团队确定的hiv感染患者队列中潜在药物相互作用的频率和严重程度。
目的:抗逆转录病毒治疗(ART)和药物之间的相互作用是艾滋病毒感染患者关注的问题。本研究旨在确定在我们的环境中与ART发生潜在药物-药物相互作用(pddi)的频率和严重程度。方法:多学科团队对1259例HIV患者(2015年3月- 2016年9月)进行观察性研究。收集了人口统计学、有毒习惯、合并症和当前抗逆转录病毒治疗的数据。一份结构化的问卷记录了伴随用药情况(包括偶尔用药和非处方药)。pddi分为四类:(1)无相互作用,(2)轻度(临床无显著性),(3)中度(需要密切监测或药物修改/剂量调整),(4)重度(禁忌)。统计分析:卡方检验、logistic回归分析。结果:881例(70%)患者服药,563例(44.7%)患者PDDI≥。41例(4.6%)患者有重度pddi, 522例(59.2%)有中度pddi。中度pddi主要涉及心血管(53.8%)和中枢神经系统(40.2%)药物。pddi的独立危险因素是ART含有增强的蛋白酶抑制剂(优势比[OR]=9.11, 95%可信区间[CI] 5.15-16.11;p = 0.0001)和/或非核苷逆转录酶(NNRTI) (or = 4.34, 95%CI 2.49-7.55;p = 0.0001),丙肝病毒合并感染(或= 3.26,95% ci 2.15 - -4.93;p = 0.0001),使用两种或两种以上药物(or = 3.36, 95%CI 2.27-4.97;p = 0.0001)。有和没有pddi的患者ART的依从性和有效性相似。该小组提出了133项与药物(药物改变或剂量调整)或ART(药物转换或改变给药计划)有关的建议。结论:系统评估发现,在接受抗逆转录病毒治疗的艾滋病毒患者中,有很大比例的pddi需要干预。对药物-药物相互作用的监测和建议应成为常规做法的一部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
HIV Clinical Trials
HIV Clinical Trials 医学-传染病学
CiteScore
1.76
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: HIV Clinical Trials is devoted exclusively to presenting information on the latest developments in HIV/AIDS clinical research. This journal enables readers to obtain the most up-to-date, innovative research from around the world.
期刊最新文献
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006). Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1